Книги
  • @
  • «»{}∼
Combination Studies With The Vascular Disrupting Agent CA4P

Combination Studies With The Vascular Disrupting Agent CA4P

31913851
7678 руб.
Добавить в корзину
Описание
This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.
Clinical Studies combined with chemotherapy and radioimmunotherapy, and DCE-MRI and immunohistochemistry correlation